Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.56 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 5/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 4/20 | 0.47 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | STAT6 | P42226 | 3/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14974313 | 0.90 | STAT6 (0.57) | JAK3JAK1SYKMAP4K3MAP4K1 | |
| SCHEMBL914805 | 0.83 | JAK3 (0.57) | JAK3JAK1SYKSTAT6 | |
| SCHEMBL20760009 | 0.80 | JAK3 (0.55) | JAK3SYKPTK2PTK2BSTAT6 | |
| SCHEMBL913836 | 0.80 | JAK1 (0.52) | JAK3JAK1SYKMAP4K3MAP4K1 | |
| SCHEMBL914262 | 0.80 | JAK1 (0.48) | JAK3JAK1SYKMAP4K3MAP4K1 | |
| SCHEMBL20759881 | 0.79 | JAK3 (0.53) | JAK3SYKPTK2PTK2BSTAT6 | |
| SCHEMBL30121827 | 0.79 | JAK3 (0.53) | JAK3SYKPTK2PTK2BSTAT6 | |
| SCHEMBL914001 | 0.76 | JAK3 (0.65) | JAK3JAK1SYKPTK2STAT6 | |
| SCHEMBL22261418 | 0.73 | JAK3 (0.80) | JAK3JAK1SYK | |
| SCHEMBL29622925 | 0.73 | JAK3 (0.80) | JAK3JAK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | claimed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | claimed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | JAK3 3/4885JAK1 1/4885SYK 72/4885 |
| US-20110005947-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | JAK3 3/4885JAK1 1/4885SYK 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.